检索结果-南通市图书馆

Oral Arsenic-Containing qinghuang powder:A Potential Drug for Myelodysplastic Syndromes

Chinese Journal of Integrative Medicine 2022年第8期28卷 762-768页

作者： MING Jing LIU Wei-yi XIAO Hai-yan XU Yong-gang MA Rou HU Xiao-mei Department of Hematology Xiyuan HospitalChina Academy of Chinese Medical SciencesBeijing100091China

qinghuang powder(QHP),an oral arsenic,has become an effective drug in the treatment of myelodysplastic syndromes(MDS)in Xiyuan Hospital,China Academy of Chinese Medical Sciences for many years,and the action mechanism of the compound or active ingredient AsSof QHP has been elucidated.Considering the relatively safety,chemotherapy-free and convenient oral profile,QHP is widely used in the clinical treatment for MDS patients,especially for elderly patients.In this review,the authors document the efficacy and safety of oral arsenic-containing compound QHP in the treatment of MDS,with a special focus on the association of efficacy of QHP with the cytogenetics,prognostic risk,DNA methylation,gene mutation,blood arsenic concentration,mechanism of action of AsSand the countermeasures against adverse reactions of gastrointestinal tract.

关键词： arsenic qinghuang powder myelodysplastic syndromes review Chinese medicine

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Comparing Arsenic-Containing qinghuang powder and Low-Intensity Chemotherapy in Elderly Patients with Acute Myeloid Leukemia

引用

Chinese Journal of Integrative Medicine 2023年第9期29卷 832-837页

作者： WU Yu-he XIAO Hai-yan QUAN Ri-cheng TANG Xu-dong LIU Wei-yi LYU Yan CHEN Zhuo LIU Chi HU Xiao-mei Department of Hematology Xiyuan HospitalChina Academy of Chinese Medical SciencesBeijing100091China Graduate School China Academy of Chinese Medical SciencesBeijing100700China

Objective To compare the clinical effect of arsenic-containing qinghuang powder(QHP)and low-intensity chemotherapy(LIC)in treatment of elderly acute myeloid leukemia(eAML)patients.Methods Clinical data of 80 eAML patients treated at Xiyuan Hospital of China Academy of Chinese Medical Sciences from January 2015 to December 2020 were retrospectively analyzed.The treatment scheme was designed by real world study according to patients’preference,and patients were divided into a QHP group(35 cases)and a LIC group(45 cases).The median overall survival(mOS),1-,2-,and 3-year OS rates,and incidence of adverse events were compared between the two groups.Results The mOS of 80 patients was 11 months,and the 1-,2-,and 3-year OS rates were 45.51%,17.96%,and 11.05%,respectively.The QHP and LIC groups demonstrated no significant difference in mOS(12 months vs.10 months),1-(48.57%vs.39.65%),2-(11.43%vs.20.04%),and 3-year OS rates(5.71%vs.13.27%,all P>0.05).Moreover,the related factors of mOS demonstrated no significant difference in patients with age>75 years(11 months vs.8 months),secondary AML(11 months vs.8 months),poor genetic prognosis(9 months vs.7 months),Eastern Cooperative Oncology Group performance status score≥(10 months vs.7 months)and hematopoietic stem cell transplant comorbidity index≥4(11 months vs.7 months)between the QHP and LIC groups(all P>0.05).However,the incidence of myelosuppression was significantly lower in the QHP group than that in the LIC group(28.57%vs.73.33%,P<0.01).Conclusions QHP and LIC had similar survival rates in eAML patients,but QHP had a lower myelosuppression incidence.Hence,QHP can be an alternative for eAML patients who do not tolerate LIC.

关键词： acute myeloid leukemia elderly qinghuang powder low-intensity chemotherapy Chinese medicine

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Clinical Observation of the Treatment of Myelodysplastic Syndrome Mainly with qinghuang powder(青黄散)

引用

Chinese Journal of Integrative Medicine 2011年第11期17卷 834-839页

作者：徐述麻柔胡晓梅许勇钢杨晓红王洪志孙淑贞刘锋 Department of Hematology Xiyuan Hospital China Academy of Chinese Medical Sciences

Objective： To observe the clinical effectiveness of qinghuang powder （青黄散, QHP） combined with Bupi Yishen Decoction （补脾益肾汤 BPYS） in treating myelodysplastic syndrome （MDS）, and its relationship with France, America, and Britain （FAB） type, international prognosis scaling system （IPSS） risk, and chromosome karyotype. Methods： There were 124 MDS patients subjected to the tests. By FAB typing, 91 patients were typed as refractory anemia （RA） type and 33 as refractory anemia with excess of blasts （RAEB） type; by IPSS scale, 21 were sorted to low risk, 77 to moderate risk I, 20 to moderate risk ]], and 6 to high risk; 78 of them had normal chromosome and 46 with abnormal chromosome, including 26 of trisomy 8. All patients were treated with QHP＋BPYS, and the changes of peripheral blood figure and bone marrow were observed. Results： After treatment, the general effective rate was 72.58% （90/124）, which in the patients of RA type was 80.22% （73/91） and in RAEB type 51.52% （17/33）. The former was better than that in the later （P〈0.01）. For the analysis in the patients of different IPSS risk degrees, the effective rate was 95.24% （20/21） in the low- risk group, 72.73% （56/77） in moderate risk I, 65.00% （13/20） in moderate-risk 11, and 16.67% （1/6） in high- risk group. Those in the first two groups were superior to that in the latter two （P〈0.01）. The effective rate was 79.49% （61/78） in the patients with normal chromosome and was 60.87% （28/46） in the patients with abnormal chromosome, showing a significant difference between them. While in the patients of trisomy 8, it was 73.08% （19/26）, which was parallel to that in the patients with normal chromosome. Conclusion： The effectiveness of QHP＋BPYS comprehensive therapy for MDS is unquestionably good, and it is markedly correlated with the FAB type and IPSS risk degree of the disease, as well as the normality of chromosome in the patient.

关键词： myelodysplastic syndrome qinghuang powder realgar Bupi Yishen Decoction clinical effectiveness

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：